We have located links that may give you full text access.
Case Reports
Journal Article
Research Support, U.S. Gov't, P.H.S.
Severe adenoviral nephritis following bone marrow transplantation: successful treatment with intravenous ribavirin.
Bone Marrow Transplantation 1993 October
Invasive adenovirus infection is recognized as an unusual cause of serious end-organ sequelae following BMT. Because symptomatic therapy may be inadequate for more serious infections, the use of investigational agents is justified. We describe a case of severe, progressive nephritis secondary to adenovirus serotype 11 following BMT. Treatment with i.v. ribavirin led to prompt clinical improvement and resolution of adenovirus excretion.
Full text links
Related Resources
Trending Papers
Challenges in Septic Shock: From New Hemodynamics to Blood Purification Therapies.Journal of Personalized Medicine 2024 Februrary 4
Molecular Targets of Novel Therapeutics for Diabetic Kidney Disease: A New Era of Nephroprotection.International Journal of Molecular Sciences 2024 April 4
The 'Ten Commandments' for the 2023 European Society of Cardiology guidelines for the management of endocarditis.European Heart Journal 2024 April 18
A Guide to the Use of Vasopressors and Inotropes for Patients in Shock.Journal of Intensive Care Medicine 2024 April 14
Diagnosis and Management of Cardiac Sarcoidosis: A Scientific Statement From the American Heart Association.Circulation 2024 April 19
Essential thrombocythaemia: A contemporary approach with new drugs on the horizon.British Journal of Haematology 2024 April 9
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app